Abstract：
In recent years, various aspects of prostate cancer (PC) management have undergone significant changes, including the implementation of therapeutic strategies such as the use of new hormonal agents like abiraterone, apalutamide, enzalutamide or darolutamide and the incorporation of next generation imaging techniques (NGI). However, the evidence regarding the role of NGI and the therapeutic decision-making based on their findings is not solid. Following the methodology of the Advanced Prostate Cancer Consensus Conference (APCCC), a multidisciplinary expert consensus was developed to address controversial questions concerning the use of NGI and clinical management in four priority scenarios: localized PC, PC after radical prostatectomy, PC after radiotherapy with curative intent, and metastatic hormone-sensitive PC. This consensus represents the opinions of medical oncology, radiation oncology and urology physicians and provides useful recommendations for clinical practice.
摘要：
近年来,前列腺癌（PC）管理的各个方面都发生了重大变化，包括实施治疗策略，例如使用新的激素药物，如阿比特龙，阿帕鲁胺,恩杂鲁胺或达鲁鲁胺和下一代成像技术（NGI）的掺入。然而,关于NGI的作用和基于其发现的治疗决策的证据并不可靠.遵循晚期前列腺癌共识会议（APCCC）的方法，制定了多学科专家共识，以解决有关在四个优先方案中使用NGI和临床管理的有争议的问题：本地化PC，前列腺癌根治术后PC,具有治愈性的放疗后PC，和转移性激素敏感型PC。这种共识代表了医学肿瘤学的观点，放射肿瘤科和泌尿科医生，并为临床实践提供有用的建议。
